Michaels J E, Schimmel P, Shiba K, Miller W T
Department of Physiology and Biophysics, School of Medicine, State University of New York, Stony Brook 11794, USA.
Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14452-5. doi: 10.1073/pnas.93.25.14452.
Dominant negative inhibition is most commonly seen when a mutant subunit of a multisubunit protein is coexpressed with the wild-type protein so that assembly of a functional oligomer is impaired. By analogy, it should be possible to interfere with the functional assembly of a monomeric enzyme by interfering with the folding pathway. Experiments in vitro by others suggested that fragments of a monomeric enzyme might be exploited for this purpose. We report here dominant negative inhibition of bacterial cell growth by expression of fragments of a tRNA synthetase. Inhibition is fragment-specific, as not all fragments cause inhibition. An inhibitory fragment characterized in more detail forms a specific complex with the intact enzyme in vivo, leading to enzyme inactivation. This fragment also associated stoichiometrically with the full-length enzyme in vitro after denaturation and refolding, and the resulting complex was catalytically inactive. Inhibition therefore appears to arise from an interruption in the folding pathway of the wild-type enzyme, thus suggesting a new strategy to design dominant negative inhibitors of monomeric enzymes.
显性负抑制最常见于多亚基蛋白的突变亚基与野生型蛋白共表达时,从而导致功能性寡聚体的组装受损。以此类推,通过干扰折叠途径应该有可能干扰单体酶的功能组装。其他人的体外实验表明,单体酶的片段可能用于此目的。我们在此报告,通过表达一种tRNA合成酶的片段对细菌细胞生长产生显性负抑制。抑制具有片段特异性,因为并非所有片段都会导致抑制。一个经过更详细表征的抑制性片段在体内与完整酶形成特定复合物,导致酶失活。该片段在体外变性和复性后也与全长酶按化学计量结合,所得复合物无催化活性。因此,抑制似乎源于野生型酶折叠途径的中断,从而提示了一种设计单体酶显性负抑制剂的新策略。